Research programme: arenicin-3 antibacterials - Adenium Biotech

Drug Profile

Research programme: arenicin-3 antibacterials - Adenium Biotech

Alternative Names: AA 139; AA230; Arenicin-3; NZ 17000; NZ 17143; NZ 17211; NZ17074

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novozymes A/S
  • Developer Adenium Biotech; Novozymes A/S
  • Class Peptides
  • Mechanism of Action Bacterial outer membrane protein modulators; Bacterial protein inhibitors; Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Intra-abdominal infections
  • Research Gonorrhoea
  • No development reported Gram-negative infections; Pneumonia; Urinary tract infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-negative-infections in Denmark (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumonia in Denmark (Inhalation, Aerosol)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Urinary-tract-infections in Denmark (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top